CHANGCHUN BCHT BIOTECHNOLOGY CO. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.23 CNY | -4.20% |
|
-9.11% | -43.02% |
| Sales 2024 * | 2.47B 341M | Sales 2025 * | 3.02B 417M | Capitalization | 13.49B 1.86B |
|---|---|---|---|---|---|
| Net income 2024 * | 710M 97.98M | Net income 2025 * | 931M 128M | EV / Sales 2024 * | 5.45 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 4.46 x |
| P/E ratio 2024 * |
19
x | P/E ratio 2025 * |
14.5
x | Employees | 1,241 |
| Yield 2024 * |
0.94% | Yield 2025 * |
1.24% | Free-Float | 21.55% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.57% | ||
| 1 week | -5.12% | ||
| Current month | -4.12% | ||
| 1 month | -16.56% | ||
| 3 months | -39.01% | ||
| 6 months | -43.12% | ||
| Current year | -40.52% |
1 week
32.50
34.88
1 month
32.5041.78
Current year
32.5058.50
1 year
32.5068.50
3 years
32.50135.88
5 years
32.50135.88
10 years
32.50135.88
| Managers | Title | Age | Since |
|---|---|---|---|
Wei Kong
CEO | Chief Executive Officer | 59 | 03-12-31 |
Zhao Feng Meng
DFI | Director of Finance/CFO | 60 | 19-01-31 |
Da Qiang Feng
CHM | Chairman | 58 | 04-02-29 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiu Feng Li
BRD | Director/Board Member | 55 | 04-02-29 |
Xing Gong Zhu
BRD | Director/Board Member | 57 | 21-08-02 |
De Shen Zhang
BRD | Director/Board Member | 60 | 19-02-20 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +4.32% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-05 | 31.23 | -4.20% | 4 505 415 |
| 24-06-05 | 32.6 | -1.57% | 2,691,297 |
| 24-06-04 | 33.12 | -0.12% | 3,038,387 |
| 24-06-03 | 33.16 | -2.47% | 3,399,727 |
| 24-05-31 | 34 | -1.13% | 2,258,164 |
End-of-day quote Shanghai S.E., June 04, 2024
More quotes
Changchun BCHT Biotechnology Co is a China-based innovative biomedical company mainly dedicated to the prevention and treatment of infectious diseases. The Company is mainly engaged in the research and development, production and sales of human vaccines. The Company has three approved vaccine products: varicella vaccine, rabies vaccine and freeze-dried nasal spray flu vaccine. The Company also has other vaccines under development and fully human monoclonal antibody under development for the prevention and control of infectious diseases. The Company mainly conducts business within the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
32.6
CNY
Average target price
54.56
CNY
Spread / Average Target
+67.38%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -40.52% | 1.86B | |
| +19.88% | 80.67B | |
| +13.63% | 9.17B | |
| -15.14% | 4.86B | |
| +45.17% | 4.55B | |
| +15.70% | 4.34B | |
| +15.11% | 2.38B | |
| -26.13% | 2.2B | |
| +15.73% | 2.1B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 688276 Stock
